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SUMMARY 
Oligopeptide ‘2A’ and ‘2A-like’ sequences (‘2As’; 18-25aa) are found in a range of RNA virus 
genomes controlling protein biogenesis through ‘recoding’ of the host-cell translational 
apparatus. Insertion of multiple 2As within a single open reading frame (ORF) produces multiple 
proteins, hence 2As have been used in a very wide range of biotechnological and biomedical 
applications. During translation, these 2A peptide sequences mediate a eukaryote-specific, self-
“cleaving” event, termed “ribosome skipping” with very high efficiency. A particular advantage 
of using 2As is the ability to simultaneously translate a number of proteins at an equal level in all 
eukaryotic systems although, naturally, final steady-state levels depend upon other factors – 
notably protein stability. In contrast, the use of internal ribosome entry site (IRES) elements for 
co-expression results in an unbalanced expression due to the relative inefficiency of internal 
initiation. For example, a 1:1 ratio is of particular importance for the biosynthesis of the heavy-
chain and light-chain components of antibodies: highly valuable as therapeutic proteins. 
Furthermore, each component of these ‘artificial polyprotein’ systems can be independently 
targeted to different sub-cellular sites. The potential of this system was vividly demonstrated by 
concatenating multiple gene sequences, linked via 2A sequences, into a single, long, ORF – a 
polycistronic construct. Here, ORFs comprising the biosynthetic pathways for violacein (5 gene 
sequences) and -carotene (4 gene sequences) were concatenated into a single cistron such that 
all components were co-expressed in the yeast Pichia pastoris. In this review, we provide useful 
information on 2As to serve as a guide for future utilities of this co-expression technology in 
basic research, biotechnology and clinical applications.  
List of Abbreviations: ACT, adoptive T-cell transfer; AAV, adeno-associated vector; BaMV, 
bamboo mosaic virus; BPMV, bean pod mottle virus; CAR, chimeric antigen receptor; CCR5, 
chemokine receptor 5; CEA, carcinoembryonic antigen; CIB1, calcium and integrin-binding 
protein 1; CP, coat protein; CRISPR, clustered regularly interspaced short palindromic repeat; 
CRY2, cryptochrome 2; CTLA-4, cytotoxic T lymphocyte antigen-4; dsB, double-strand break; 
EDIII, envelope protein domain III; EGFR, epidermal growth factor receptor; ER, endoplasmic 
reticulum; eRF, eukaryotic release factor; FMDV, foot-and-mouth disease virus; GFP, green 
fluorescent protein; HDR, homology directed repair; HCV, hepatitis C virus; IDLV, integrase-
defective lentiviral vector; Ig, immunoglobulin; IL, interleukin; 4-IPO, 4-ipomeanol; iPSC, 
induced pluripotent stem cell; IRES, internal ribosome entry site; JEV, japanese encephalitis 
virus; mAb, monoclonal antibody; LOV, light, oxygen and voltage; MAARGE, multiplexable 
activation of artificially repressed genes; MAPK, mitogen-activated protein kinase; MHC, major 
histocompatibility complex; MSTN, myostatin; MUC1, mucin-1; NHEJ, non-homologous end 
joining; NILV, non-integrating lentivirus; NLR, NOD-like receptor; NOD, nucleotide-binding 
oligomerization domain; ORF, open reading frame; PhyB, phytochrome B; PVX, potato virus X; 
RGN, RNA-guided nuclease; RNA, ribonucleic acid; scFv, single-chain variable fragments; 
TALEN, transcription activator-like effector nuclease; TCR, T-cell receptor; TIL, tumour 
infiltrating lymphocytes; TLR, traffic light reporter; UVR8, ultraviolet-resistance locus 8; ZFN, 
zinc finger nuclease. 
 
 
 
1 – INTRODUCTION 
The 2A/2Alike peptide sequences found in a number of RNA viruses share a highly conserved 
motif: -D[V/I]E(X)NPG

P-, where “X” = any amino acid and  indicates the site of ‘cleavage’ 
between the C-terminal glycine of 2A and the N-terminal proline of the downstream protein.  We 
have shown that 2A is not a proteinase, nor a substrate for a host-cell proteinase, but is an 
autonomous element mediating a novel co-translational “recoding” event.1-5 Briefly, our model 
proposes that during the elongation phase of translation, the nascent 2A sequence interacts with 
the ribosome exit tunnel to bring about a reorientation of the peptidyl-tRNA ester linkage in the 
peptidyl-transferase centre of the ribosome precluding it from nucleophilic attack by prolyl-
tRNA.  In this manner, the normal process of peptide bond formation between the glycine and 
the proline residues is prevented. Although no stop codon is involved, yeast genetic screens  for the 
involvement of host-cell factors in the ‘cleavage’ mechanism showed that eukaryotic translation release 
factors 1 and 3 (eRF1/3) played a key role in the release of nascent protein from the ribosome at the C-
terminus of 2A.
6-8
 However, Machida and co-workers showed that processing of encephalomyocarditis 
virus (EMCV) proteins 2A and 2B in a reconstituted in vitro translation system does indeed occur in the 
elongation phase of translation – but without the involvement of eRFs.9  Whilst the basis of this 
discrepancy remains unclear, this does not impact upon the utility of the system.  Termed “ribosome 
skipping”10 or “stop carry-on” translation,6 our model of this translational recoding event 
predicts two outcomes subsequent to release of the nascent polypeptide: (i) translation of the 
downstream sequences resumes, or, (ii) ribosomes terminate translation. A third (minor) 
outcome is that 2A does not mediate a recoding event and the peptide bond between 2A and the 
down-stream sequence is formed in the normal manner – an outcome dependent upon the length 
of 2A and sequence variants. For an in-depth review of the model see reference
 
11. In support of 
our co-translational model of 2A-mediated ‘cleavage’, any signal sequences immediately 
downstream of 2A are recognised by signal recognition particle to target that protein to the 
exocytic pathway.
12
 Highly efficient co-expression in association with the ability to 
independently target the individual protein ‘cleavage’ products to different subcellular 
compartments greatly enhances the versatility of the 2A system.
12-15
 
The first 2A peptide sequence identified was from the picornavirus foot-and-mouth disease virus 
(FMDV: “F2A”).16 Measuring the activity of 2A/2A-like sequences usually involves artificial 
self-processing polyproteins comprising reporter proteins flanking the 2A sequence in a single 
ORF.
17
 Site-directed mutagenesis showed the conserved amino acid sequence, NPGP, is critical 
for activity.
2,4,18,19 
Analyses of natural synonymous codon usage of this –NPGP-  motif show  
preferential  usage of AAC, CCT, GGG and CCC codons, respectively,
20 
 specific silent mutation 
of the codon encoding the glycine showed no effect
21
. Furthermore, manifold silent point 
mutations introduced within this motif for biotechnological purposes (to reduce the probability 
of deletion through recombination in the case where multiple 2As are used) have no effect on 2A 
‘cleavage’.    
Caveats of the 2A system are that (i) proline forms the N-terminal residue of the protein 
downstream of 2A and (ii) 2A remains as a C-terminal extension on the protein upstream of 2A. 
These factors must be taken into consideration during construct design with regard to necessary 
post-translational modifications, trafficking or function - which may be overcome by correct 
order of the gene sequences.
22-24
   For proteins passing through the exocytic pathway, inclusion 
of a furin proteinase cleavage site (-
↓
RX[K/R]R-) between the upstream protein and 2A results in 
efficient removal of the 2A peptide.
25,26
   Similarly, in plants the 2A C-terminal extensions are 
removed by inclusion of a linker (-SN
↓
AADEVAT-) cleaved by an endogenous proteinase.
27,28
 
Antibodies have, however, been generated against 2A, serving as a useful probe for 2A “tags”.22 
F2A is widely used for co-expression, although other highly efficient “2A-like” peptides have 
been identified and are also widely used in biotechnology and biomedicine: T2A from Thosea 
asigna virus, P2A from porcine teschovirus-1 and E2A from equine rhinitis A virus (Figure 
1).
29,30
 Many researchers employ a ‘spacer’ sequence between the upstream protein and 2A: the 
V5 epitope tag: -GKPUPNPLLGLDST-,
31
 a 3xFLAG epitope tag: -DYKDHDG-DYKDHDI-
DYKDDDDK-,
32
 or a glycine-serine linker: -GSG- or –SGSG-.13,33 
This technology has been critical for expression of hetero-multimeric complexes and 
biochemical pathways in diverse areas such as human cancer gene therapies, production of 
induced pluripotent stem cells for regenerative medicine, creation of transgenic animals and 
plants and the production of high-value proteins for the pharmaceutical industry.
30,34
 Below, we 
consider select studies to highlight current advances in this fast-moving technology. 
2 - PLANT-BASED VACCINES AND ANTIBODIES 
Plants are used as bioreactors to express a range of high-value proteins such as vaccine antigens 
and antibodies (‘plantibodies’).35-37 Stable expression is accomplished by transformation of plant 
genomes, although plant viral vectors can produce high-level, transient, expression (without the 
creation of a genetically modified organism). Expression systems based on plant viruses include: 
epitope presentation systems in which the short antigenic peptide is fused to the viral coat protein 
(CP) and displayed on the surface of the virion – so-called ‘overcoat’ technology. Advantages of 
this approach are the relative ease with which modified viral particles can be purified from 
infected tissues and the presentation of multiple copies of an antigenic peptide on the surface of a 
macromolecular carrier, significantly increasing its immunogenicity.
38,39
  
The helical rod-shaped potato virus X (PVX) CP as a presentation system was first demonstrated 
using green fluorescent protein (GFP). Expression of a simple [CP-GFP] fusion protein produced 
no virus particles. Linking the CP and GFP via a short, less efficient, version of F2A [CP-F2A16-
GFP] resulted in the production of free CP plus the [GFP-F2A16-CP] fusion protein. Fully 
infectious virus particles ‘decorated’ with GFP were produced.40 It is thought that the fusion 
protein (alone) cannot initiate the helical rod capsid structure, but having a mixture of the fusion 
protein plus the capsid protein allows the latter to initiate particle (rod) formation, which is then 
able to incorporate the fusion protein. Having established the utility of the approach, several 
types of protein have been expressed on the surface of these particles; rotavirus inner capsid 
protein (VP6),
41 
tuberculosis ESAT-6 protein,
42
 classical swine fever virus E2 glycoprotein
43 
and 
the R9 peptide from hepatitis C virus (HCV) envelope protein.
44
 Other than these antigenic 
proteins, particles have been decorated with a single-chain antibody (scFv; Mr~25,000) or the 
enzyme lipase (CalB, Mr 33,000).
45,46
           
In a recent study, Chen et al reported the use of a bamboo mosaic virus (BaMV)-based vector 
with the capacity to carry larger transgene loads than the PVX-based vector.
47
 Using the BaMV 
as a plant viral display vector, the Japanese encephalitis virus (JEV) envelope protein domain III 
(EDIII) was genetically linked to the CP of BaMV via a F2A18 sequence (Figure 2). Upon 
infection in the leaves of Chenopodium quinoa, the BaMV plant host, the EDIII peptide was 
displayed on virion surfaces. Most importantly, the chimeric virus was able to induce immune 
responses in mice and protection against JEV infection. 
The development of an anti-Taenia solium cysticercosis vaccine in transgenic plant tissue 
extracts by Monreal-Escalante et al. used a 2A-based polyprotein system for the simultaneous 
delivery of several Taenia spp. antigens (KETc1, KETc12, KETc7, GK1, TSOL18) via 
Agrobacterium tuefaciens transformation.
48
 The plant derived vaccine was recognised by 
antibodies in the cerebrospinal fluid from neurocysticercosis patients and induced antigen-
specific antibodies in the sera of BALB/c immunized mice. Here, the same F2A amino acid 
sequence was used as the linkers. To minimise the risk of homologous recombination and 
genetic instability, others have used either (i) different 2A-like sequences or (ii) different codon 
usages for the same 2A. For example, in soybean-infecting bean pod mottle virus (BPMV) 
vectors, non-identical nucleotide sequences encoding the same F2A were used.
49
     
In the case of passive immunity, plantibodies have been expressed for therapeutic applications.
50
 
Since the expression and assembly of immunoglobulin (Ig) heavy and light chains into functional 
murine antibodies was first demonstrated in Nicotiana tabacum,
51
 plant-based expression 
systems have proved to be an attractive platform for the production of full-size antibodies and 
their derivatives.
52-55
 In a biosimilar study, Chen and colleagues designed and expressed a 
biologically functional monoclonal antibody (mAb; bevacizumab) in transgenic rice callus using 
the 2A peptide.
56
 This anti-angiogenic agent has been widely used in clinical practice for the 
treatment of different cancers, slowing the growth of new blood vessels in tumours.
57
 To make a 
polyprotein the authors inserted a F2A18 sequence between codon optimized heavy-chain and 
light-chain sequences of bevacizumab. In an attempt to avoid plant-specific glycosylation (an 
important issue for antibodies made in plant expression), an ER retention signal peptide (KDEL) 
was added to the C-termini of both gene sequences. A balanced heavy:light  chain ratio allowed 
efficient assembly and folding of functional antibody, producing recombinant mAb at high 
levels. However, the C-terminal 2A extension on the protein upstream of 2A resulted in the loss 
of recognition of the KDEL signal – a furin proteinase cleavage site between the KDEL and 2A 
sequences (to remove the 2A) may have improved the ER retention problem, although furin is 
located primarily in the Golgi apparatus. This first plant-expressed bevacizumab might 
potentially be used as a cost-effective “biobetter” molecule in future cancer treatments.  
3 - ADOPTIVE T-CELL ANTI-CANCER IMMUNOTHERAPY 
T-cells play a central role in cell-mediated immunity. Adoptive T-cell transfer (ACT), based on 
the manipulation and transfusion of autologous or allogeneic immune cells into patients is 
currently being tested in numerous clinical trials. Approaches include the use of tumour-
infiltrating lymphocytes (TILs) and ex vivo-engineered T-cells, such as T-cell receptor (TCR), 
chimeric antigen receptor (CAR) and synthetic Notch (synNotch) receptor transduced T-cells 
(reviewed in
 
58-60). Adoptive cell therapy with TILs in combination with lymphodepleting 
regimens and the use of interleukin-2 (IL-2) to sustain T-cell expansion has shown some success 
in the treatment of metastatic melanoma.
61
  However, such a process is laborious and time-
consuming and is limited to those patients for whom tumour-specific T-cells can be isolated and 
amplified. One promising strategy to expand the range of ACT is to administer T-cells that have 
been genetically modified to express tumour-specific antigen receptors. 
The TCR  heterodimer detects antigenic peptides in the context of major histocompatibility 
complex (MHC) proteins and signals through the non-covalently associated CD3, CD3 and 
 dimers. Both endogenous and transgenic TCRs require a complementary activating/inhibitory 
co-stimulatory signal, in effect, functioning as an on/off switch to regulate T-cell activity 
(reviewed in
 
62). 2A peptides have been widely adopted for TCR gene therapy because of their 
near-stoichiometric expression of both TCR andchains.14,31,63 Further, exposure to the most 
widely used 2A sequences is unlikely to produce unwanted T-cell responses in 
immunocompetent subjects and supports their continued use for gene therapy studies.
64,65
 A 
potential drawback to effective immunotherapy is mispairing between introduced and 
endogenous TCR chains, resulting in unexpected specificities and reduced cell surface levels of 
transferred TCRs.
66,67
 A number of TCR modifications have been reported to minimise the 
extent of mispairing, including the introduction of a disulphide bond between cysteines
68
 and 
codon optimisation of the transgenic TCR to enhance mRNA translation and protein synthesis.
69
 
To reduce the mismatch, knockdown or knockout of endogenous TCR- gene expression has 
been achieved using small-interfering RNA (siRNA) technology (siTCR vector).
70,71 
The 2A 
peptide-based siTCR vector simultaneously transduces codon-optimised therapeutic TCRs [-
T2A-] and siRNA constant regions of intrinsic TCR- gene sequences. Notably, the siTCR 
either alone or in combination with extra cysteines (introduced by site-directed mutagenesis) 
markedly increases the cell-surface expression of the introduced TCR.
71
     
Another promising strategy to broaden the utility of ACT is to administer T-cells that have been 
genetically engineered to express CARs, which are antibody single-chain variable fragments 
(scFv) joined with TCR and T-cell co-stimulatory receptor signal domains targeting cell-surface 
antigens in an MHC-independent fashion. Unlike TCRs, co-stimulation is provided in cis and in 
response to the same activating signal. Investigators have generated CARs targeted to various 
tumour antigens, such as carcinoembryonic antigen (CEA), epidermal growth factor receptor 
(EGFR), CD19 (leukaemia and lymphoma), or viral-associated cancer antigens (reviewed in 72). 
The modular design of the CAR, extracellular ligand-binding domain fused through a flexible 
hinge and transmembrane motif to intracellular signalling components, allows optimisation of T-
cell function. The successful use of an CEA-CAR 2A-based bicistronic vector in a mammalian 
cell-screening protocol for the isolation of functional scFvs highlights how this approach could 
also be used to improve the expression and binding of scFvs.
73 
Empiric testing of hinge length 
and sequence, vis-à-vis epitope position, is required to determine the most favourable CAR 
design.
74,75
 For example, modification of the IgG4 Fc “spacer” domain in a CD19CAR-T2A-
EGFRt construct reduced “off-target” activation and improved in vivo persistence and anti-
tumour strength of adoptively transferred T-cells.
76,77
     
Compact combined sort-suicide gene strategies based on transgenic expression of a binding 
target for a therapeutic antibody have been proposed for easier and safer T-cell therapy. For 
instance, truncated EGFR paired with the IgG1 mAb cetuximab may be used as a non-
immunogenic selection tool, an in vivo tracking marker and a suicide gene for transduced 
[CD19CAR-T2A-EGFRt] T-cells.
76-78
 As an enhancement of this CAR, a small marker/suicide 
gene (RQR8) was created by combining epitopes from CD34 and CD20 enabling CD34 
selection, cell tracking, as well as depletion after anti-CD20 mAb (rituximab) targeting [RQR8-
T2A-GD2CA].79 For clinical applications, a novel suicide gene system based on bio-activation 
of 4-ipomeanol (4-IPO) was recently developed as a pro-drug with active human mutant 
CYP4B1 enzyme.
80 
This enzyme converts the inert substrate into highly toxic DNA alkylating 
metabolites.
81 
For the use of CYP4B1 in combination with a CAR, the lentiviral vector expressed 
a codon-optimised CD19 CAR upstream or downstream of the T2A site. 
Although T-cells expressing CARs have shown exciting promise in the treatment of some 
refractory diseases, there is ample scope for improvement. For example, several cytokines (e.g. 
IL-2, IL-12 and IL-15) are currently being tested as combination partners that may improve the 
activity and/or survival of CAR-T cells.
82 
Specifically, Wilkie at al. showed that IL-4 
administration can be used to achieve rapid and selective ex vivo expansion and sustained anti-
tumour activity of human T-cells engineered to co-express a chimeric IL-4 receptor (4) fused 
to a CAR specific for tumour-associated MUC1 (HOX) via T2A (Figure 3).
83
 A concern with 
ACT is the proliferation of endogenous T cells in relation to gene-modified cells following 
transfer in vivo. To improve in vitro/in vivo selection of therapeutic cells, target cells were 
transduced with a vector containing the hEGFRt marker gene along with two drug-resistance 
genes. One gene is a variant of the inosine monophosphate dehydrogenase 2 (IMPDH
IY
; T333I, 
S351Y), conferring resistance to the immunosuppressive drug mycophenolate mofetil. The other, 
a human dihydrofolate reductase (DHFR
FS
; L22F, F31S), confers resistance to methotrexate.
78
 In 
this study, engraftment of [EGFRt-T2A-DHFR
FS
-T2A-IMPDH
IY
] T-cells supported the 
preferential expansion and selection of transduced over non-transduced human T-cells following 
drug administration to mice. 
To increase the specificity of engineered T-cells researchers have used synNotch receptors, 
which consist of the small regulatory domain of Notch combined with bespoke extracellular and 
intracellular signalling domains.
84-86
 The most prominent inhibitory co-stimulatory receptors are 
cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed cell death protein 1 
(PD-1). Strategies to overcome this “adaptive resistance” of infused T-cells boosts their 
responses by preventing exhaustion and anergy.
87
 In one approach, synthetic T-cells were 
engineered with the -GFP synNotch receptor controlling the expression of both anti-PD-1 and 
an scFv directed toward CTLA-4 – both antibodies were expressed as a single transcript linked 
via T2A.
60
 A dual pathway blockade could have a synergistic effect, because CTLA-4 and PD-1 
modulate different aspects of the T-cell response.
88
 Additional complementary immune therapies 
include antigen-specific production of immunosuppressive agents in an autoimmune-associated 
setting. Here, the -CD19 synNotch receptor, when stimulated, induced the expression of [PD-
L1-T2A-IL-10].
60
 As the main ligand for PD-1, PD-L1 induces a co-inhibitory signal in activated 
T-cells and also stimulates cytokine IL-10 production, further reducing the immune response.
89  
  
4 - GENE THERAPY BY ENGINEERED NUCLEASES 
Three major programmable nuclease platforms exist: zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and RNA-guided nucleases (RGNs) (reviewed in 90-
92)    The double-strand break (dsB) made by these targetable nucleases is typically repaired 
through one of two major pathways – non-homologous end joining (NHEJ) or homology 
directed repair (HDR).
93
 ZFNs and TALENs are similar and comprise a FokI derived nuclease 
domain coupled to a DNA binding domain engineered to recognize a specific sequence.
94,95 
The 
clustered regularly interspaced short palindromic repeat (CRISPR)/Cas RGNs rely on base-
pairing between a “guide” RNA and the DNA target for recognition and a Cas nuclease for DNA 
cleavage.
90,96
  
Regardless of the nuclease system used, it is essential to have methods that can select or enrich 
genome-modified cells. Several  approaches using 2A have been applied to aid selective 
enrichment of transfected cells, including fusion of ZFNs/TALENs and Cas9 to a fluorescent or 
antibiotic protein,
97-101
 or, co-transfection of the nucleases with a fluorescent or antibiotic 
resistance marker gene.
100
 To recapitulate DNA nuclease activity, dual-reporter surrogate 
systems that contain the target sequence to be modified have been developed to detect cells with 
high repair efficiency.
102 
The two-colour “Traffic Light Reporter” (TLR; eGFP-T2A-mCherry) 
developed by Scharenberg and colleagues uses a flow cytometric assay to simultaneously detect 
both gene repair and mutagenic NHEJ at a single targeted site (Figure 4).
103 
HDR using a donor 
template carrying an intact eGFP results in green fluorescent cells. If mutagenic NHEJ repairs 
the break, a shift in the reading frame of the eGFP reporter can result in translation of the T2A-
mCherry, leading to red fluorescent cells.  
The advances in genome editing technologies have opened the door for an entirely new and 
promising approach to removing or correcting causative errors in therapeutic genome “surgery”. 
One of the main hurdles to using ZFNs is the effective delivery of ZFNs and donor templates to 
target cells. Among viral vectors, integrase-defective lentiviral vectors (IDLVs, also called non-
integrating lentiviral vectors),
104
 adeno-associated vectors (AAVs),
105
 and chimeric adenoviral 
vectors
106
 have been used to safely deliver the gene targeting components. Gene delivery is a 
particularly significant issue for gene correction because it is necessary to introduce three 
components into cells (e.g. two ZFNs + donor). To improve the delivery of both ZFNs to the 
same cell in equal amounts, Joglekar et al. designed a single IDLV encoding both the left and 
right ZFN monomers linked by T2A and linked to mCherry via P2A, to monitor gene transfer 
and expression by flow cytometry.
107 
By introducing DNA sequence changes to reduce 
homology between the two ZFNs, this study achieved delivery of both monomers by one IDLV. 
Independently, envelope pseudotyped non-integrating lentivirus (NILV) was used for co-
expression of ZFNs to edit the chemokine receptor 5 (CCR5) gene as a therapeutic strategy to 
block HIV-1 infection.
108
 CCR5 is the major co-receptor for HIV-1 entry and validated as a 
target for HIV therapy.
109
 ZFN constructs targeting both strands of CCR5 were connected via 
F2A, and then inserted into a lentivirus cloning vector. The results showed that transduced 
activated and resting T-cells resist HIV infection in vitro. Likewise, endogenous virus replication 
was suppressed in humanized mice after adoptive transfer of NILV-transduced primary T-cells 
or CD34
+
 stem cells. An alternative to using IDLV is to use AAV for delivery which, in 
comparison, is more efficient for transduction in vitro and in vivo. Although AAV has many 
advantages over other viral vectors, its relatively small packaging capacity (< 4.2kb) limits its 
use for delivering large genes. To address this, a single AAV vector, which contains DNA 
encoding two GFP ZFNs separated by a 2A peptide, and includes the donor substrate was used 
for effective delivery into mouse and human cells.
110  
  Furthermore, the feasibility of autologous 
CD4
+
 T-cell infusions modified by CCR5-specific 2A-linked ZFNs delivered with an AAV was 
demonstrated in the first bench to bedside trials in subjects infected with HIV-1.
111
            
Because Fok1 functions as a dimer, TALENs, like ZFN’s, are designed in pairs that bind 
opposing DNA target sites. Perhaps the most obvious approach for efficient genome editing is 
via 2A-linked TALEN monomers. To this end, Mariano and co-workers (2014) compared the 
gene editing performances of co-transfected TALEN-L and R versus 2A-linked TALENs 
targeting two different loci: myostatin (MSTN) and AAVS1.
99 
MSTN is a potent inhibitor of 
skeletal muscle development and growth in several mammalian species; loss of this gene 
function leads to profound muscle ‘over-growth’.112,113 TALENs targeting the MSTN gene 
expressed from one plasmid exhibited higher gene editing activity compared to co-transfection 
with the same TALENS in two separate plasmids.
99,114   
The well characterised human AAVS1 
“safe harbor” locus has been previously shown to allow stable and long-term expression of 
transgenes in multiple cell types including human pluripotent stem cells.
115,116
 Similarly, 
TALENs used for AAVS1 genome editing showed that expression from one plasmid induced 
higher gene editing activity than the co-transfected TALEN-L and R due to proper co-delivery of 
TALE monomers.  
In contrast to protein-based tools such as zinc-fingers and TALE’s, CRISPR technology is now the most 
popular genome editing tool. One of biggest advantages of the CRISPR/Cas9 system is its ability to target 
multiple sites by simply providing several distinct gRNAs along with the Cas9 protein. Multiplex editing 
offers a robust, efficient and designable approach for genome engineering including new therapeutic 
modalities.
117
 For mammalian cells, a novel strategy using multiplexable activation of artificially 
repressed genes (MAARGE) allows the fast and convenient generation of stable cell lines with defined 
expression of the gene(s) of interest, while avoiding off-target activity at different sites in the genome. 
Since the activation of gene expression occurs at low efficiency, the expression of each engineered gene 
should be coupled to the expression of a distinct fluorescent protein via a 2A peptide in order to facilitate 
enrichment of modified cells.
118
 
 
5 - OPTOGENETIC/LIGHT CONTROL OF GENE EXPRESSION IN BIOLOGICAL SYSTEMS 
The burgeoning field of “optogenetics” integrates optics and genome engineering approaches to 
control various protein-protein interactions with high spatial and temporal resolution. A variety 
of light-controlled dimerisation systems have been developed, such as LOV (light, oxygen, and 
voltage) domains,
119
 phytochrome B (PhyB),
120,121
 cryptochrome 2 (CRY2),
122
 and UV-
resistance Locus 8 (UVR8).
123,124
 Among these, the blue light-dependent binding of Arabidopsis 
CRY2 to its partner cryptochrome interacting protein (CIB1), has been the most studied as this 
system offers rapid on- and off-kinetics of protein pair binding without the need for exogenous 
co-factors. CRY2-CIB1 heterodimerisation is based on the interaction between the N-terminal 
portion of CIB1 (CIBN) and the PHR domain of CRY2 in response to blue light.
122,125
 So far, 
this approach has been used in a variety of cell lines and model systems to regulate 
transcription,
126 
signalling pathways, 
127,128
 phosphoinositide metabolism,
129
 and other cellular 
processes. 
Despite its advantages, the CRY2-CIB system has an important practical limitation – the lack of 
ratiometric control between the fusion proteins. A solution was provided in the form of a 2A-
based bicistronic optogenetic system, optimising light-activation of the Raf/MEK/ERK 
signalling cascade in PC12 cells (Figure 5).
130 
The mitogen-activated protein kinase (MAPK) 
pathway regulates cell cycle progression, survival, senescence, and migration.
131 
The 2A 
constructs contained a CRY2-mCherry-Raf1 expression cassette, the P2A peptide and CIBN-
GFP-CaaX cassette (with varying number of CIBNs, referred to as CRY2-2A-(n)CIBN). Light-
induced binding between CIBN and CRY2 leads to membrane recruitment of CRY2-mCherry-
Raf1, which activates the Raf/MEK/ERK signalling pathway and induces PC12 cell 
differentiation. The results suggest that a CIBN:CRY2 expression ratio of 2:1 is an optimal 
stoichiometry for light-induced PC12 differentiation. Additionally, the optimised [CRY2-2A-
2CIBN] system allows reversible optogenetic control of kinase activity during Xenopus 
embryonic development and demonstrates the potential utility of this system to other in vivo 
models.  
Recently, a photoactivatable Cre-loxP recombination system was developed via fusion of (i) 
truncated CR6Y2 to the N-terminal domain of Cre and (ii) fusion of CIB1 to the C-terminal 
domain of Cre. Blue light illumination causes dimerisation of CRY2 with CIB1 and 
reconstitution of split-Cre recombinase activity.
132 
More recently, a highly efficient 
photoactivatable Cre recombinase (PA-Cre) that is based on reassembly of a pair of split Cre 
fragments, each appended to photoinducible dimerisation domains named “Magnets”, has been 
validated in vitro and in vivo .
133 Both positive (pMag) and negative (nMag) “Magnets” are 
inducible dimerisation proteins (~150aa each) which heterodimerise in response to blue light 
irradiation
134
 thereby unifying the split-Cre into an active enzyme. On the basis of recombination 
efficiency, CreN59 (residues 19-59) and CreC60 (residues 60-343) fragments were used for PA-
Cre, which is different from the conventional CRY2-CIB1 split Cre system using the CreN104 
(residues 19-104) and CreC106 (residues 106-343) pair. To package PA-Cre into a more 
compact format the CreN59-nMag ORF was followed by a P2A peptide sequence and then the 
coding sequence of pMag-CreC60.  
6 – CONCLUDING REMARKS 
Over 1.100 research publications and approximately 700 patent applications attest to the influence of 2As 
on co-expression technology. Previous studies have shown that 2A works in all eukaryotic cells tested to 
date: mammalian
135,136 
plant
137
, insect
138,139
, filamentous fungi
140
, the yeast Saccharomyces cerevisiae
8
 and 
Pichia pastoris
141,142 
Although eukaryotic ribosomes are highly
 
conserved, they are not completely 
conserved. F2A, E2A and P2A have all evolved to cleave within mammalian ribosomes and yet they are 
not identical sequences. T2A has evolved to cleave within insect cells. We have proposed that 2A 
interacts with the ribosome exit tunnel, some 100Å long and between 10-20Å in width. The tunnel is 
thought to accommodate a 30aa tract (extended conformation) or up to 60aa (-helical conformation). 
Indeed, it has been shown that nascent peptides may initiate folding while located well within the 
ribosome exit tunnel.
143
  The length of 2As is, however, less than 30/60aa: gene sequences immediately 
upstream of 2A are also present within the exit tunnel: they may affect the interaction of 2A with the exit 
tunnel and, therefore, the cleavage activity. The cleavage activity of any specific 2A may, therefore, be 
somewhat different on a case-by-case basis. Interestingly, some investigators use flexible ‘linker’ 
peptides between the gene sequence and 2A (see below) – the extra (flexible) sequence may ameliorate 
any effect of gene sequences upstream of 2A. The majority of studies have primarily focused on the 
“cleavage” efficiencies of different 2As in bi-cistronic systems and obtained mixed results. This 
variability is due in part to the context of the experiment, including the, sequence of each specific 
construct, the organism and/or cell lines used: plus in the majority of cases the relative stability of the 
various translation products is unknown. We have shown T2A20 has the highest cleavage efficiency 
(~100%), followed by E2A20, P2A20 and F2A20, when compared using in vitro transcription/translation 
experiments
5
. On the other hand, Szymczak and colleagues demonstrated that F2A22 and T2A18 have 
higher efficiency (~100%) than E2A20 in a similar experimental setup
14
. When evaluated in human cell 
lines, mice, zebrafish and drosophila using western blotting/fluorescence microscopy, P2A19 exhibited the 
highest cleavage efficiency followed by T2A18, E2A20 and F2A22. 
135,138
 In S. cerevisiae, these commonly 
used sequences all showed some level of cleavage, determined by western blotting: P2A19(85%), 
T2A18(56%), E2A20(46%), F2A22(43%) – interestingly, the best performance (~100%) was achieved 
using the less-used 2A peptide from Equine rhinitis B virus (ERBV-1).
144
 The inclusion of –GSG- or –
SGS- ‘linkers’ between the first gene sequence and 2A has been shown to improve the efficiency of 
cleavage. 
14,31,32,145
 
Co-expression of multiple genes (more than two) is sometimes desired, e.g. 2A has played a 
pivotal role in the co-expression of the four transcription factors (Oct4, Sox2, c-Myc, Klf4) 
required to produce induced pluripotent stem cells (iPSCs).
146
 In longer constructs protein 
expression is mostly affected by the position of individual gene sequences rather than the 2As 
and their order, possibly due to ribosome drop-off. 
147
 Notably, if multiple, identical, 2As are to 
be used in the same construct, the risk of deletion through recombination can be reduced by 
changing the codon usage for each 2A.  
These viral 2A peptides have near 100% cleavage efficiency in artificial polyprotein systems, but 
they can be made to cleave at lower efficiencies when key amino acid residues are mutated.
4,5
 In 
some cases the presence of both cleaved and uncleaved forms can be useful or even essential: in 
the biogenesis of recombinant ‘decorated’ virus particles, for example, such a mixture is key.47 
Yu and colleagues developed a “Molecular Rheostat” system using appropriate mutant F2A 
peptides to select, or tune, the levels of membrane-bound and secreted IgG in B cells.
148
 
Subsequently, Cruz-Teran et al. demonstrated that inefficient ribosomal skipping can also be 
used for simultaneous cell surface display and secretion of proteins in Saccharomyces 
cerevisiae.
149
 Recently, we identified “2A-like” sequences at the N-terminus of certain NOD-like 
receptors (NLRs) in the genome of the purple sea urchin Strongylocentrotus purpuratus - these 
innate immune receptors provide protection of a host against pathogens. We showed these 
cellular NLR-2As could function both as a signal sequence and as a translational recoding 
element: “uncleaved” forms enter the exocytic pathway while those translational products in 
which 2A has mediated “cleavage” become localised to the cytoplasm.150,151 This represents a 
newly described form of dual protein targeting with obvious biotechnological and biomedical 
applications.  
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Figure 1. Stable antibody expression using the 2A peptide. The heavy chain (plus its signal 
sequence) and light chain (plus its signal sequence) are linked by 2A. Insertion of a furin 
recognition site upstream of 2A allows removal of 2A residues that would otherwise be attached 
to the heavy chain. Signal sequences direct the insertion of proteins into the membrane of the ER 
and are cleaved off by signal peptide peptidase (SPP). Examples of 2A/2A-like sequences used 
in biomedicine and biotechnology are shown below. 
 
Figure 2. Schematic representation of the recombinant constructs based on the BaMV 
cDNA infectious copy. Organization of the wild-type BaMV, BaMV-[EDIII-CP] and BaMV-
[EDIII-F2A-CP]. Boxes represent coding sequences. The predicted Mr values of the four 
proteins common to all constructs are indicated. Inoculation of plants with a recombinant virus 
genome encoding EDIII fused to CP [EDIII-CP] showed this genomic form to be non-infectious, 
whereas incorporation of F2A between EDIII and CP [EDIII-F2A-CP] was infectious and 
generated both EDIII-2A-CP fusion protein and free CP in plant cells. 
 
Figure 3. Co-expression of a chimeric IL-4 receptor (4and a CAR specific for tumour-
associated MUC1 (HOX) in human T-cells. (A) Co-expression of and a MUC1-specific 
CAR (HOX) was achieved using an intervening T2A peptide placed downstream of a furin 
cleavage site (-RRKR-) and SGSG linker. (B) Key features of the HOX fusion receptor are: an 
HMFG2 (human milk fat globule 2) scFv, that specifically binds to the cell surface glycoprotein 
Mucin 1(MUC1), an IgD hinge providing flexibility and a tripartite signaling domain.  
 
Figure 4. Schematic outline of the Traffic Light Reporter assay. Arrow represents promoter 
and initial GFP start codon. The reading frame of each fluorescent protein is indicated in 
superscript. GFP expression can be recovered upon HDR-mediated repair following delivery of 
an appropriate homologous template and cells will fluoresce green. If the dsB undergoes NHEJ 
repair, GFP will be translated out of frame and the T2A and mCherry sequences are rendered in 
frame – leading to mCherry production. 
 
Figure 5. Light controlled activation of the Raf/MEK/ERK signaling cascade. (A) Schematic 
of the CRY2-P2A-CIBN construct. Upon translation, one mRNA transcript generates two 
proteins: CRY2-mCherry-Raf1-P2A and CIBN-GFP-CaaX. (B) The CIBN domain is anchored 
to the plasma membrane via a CaaX motif. Upon light stimulation, CIBN-CRY2PHR interaction 
recruits cytoplasmic CRY2PHR-mCherry-Raf1 to the plasma membrane which activates the 
Raf/MEK/ERK signaling pathway. In the absence of light, spontaneous dissociation of CIBN-
CRY2PHR returns Raf1 to the cytoplasm and inactivates ERK.  
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